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Abstract: This work is part of our ongoing research in the discovery 
of multitarget therapeutic agents for Alzheimer’s disease (AD). A 
literature screening, based on our recently proposed pharmacophore, 
led to the identification of 8-aminomethyl-7-hydroxy-4-methyl 
coumarins as potential multitarget leads for AD. The results of a 
computer-assisted protocol developed by us to validate multitarget 
hits for AD indicated that our coumarin candidates were viable leads 
only for AChE inhibition as later validated by biological assays. The 
results of BChE binding and propidium displacement assays indicate 
that our first generation compounds bind to the PAS site in AChE.  
We designed new generations of coumarin derivatives with a longer 
substituent at position 8 aimed at leads with more efficient 
interaction at the catalytic anionic site (CAS). Inhibition data and 
docking simulations indicated that an anilino-capping group reached 
the CAS region of AChE and determined also a higher inhibitory 
potency towards BChE. The best compound obtained, with a N-
benzylpiperidine fragment, displayed sub-micromolar affinity for 
AChE, affinity for BChE, and precluded Aβ amyloid aggregation with 
a potency similar to that of 9,10-anthraquinone, making it a 
multitarget lead viable for further improvement.  
Introduction 
Alzheimer disease (AD), a cerebral neurodegenerative 
pathology that is the main cause of dementia in older people, is 
characterized by the progressive formation of insoluble amyloid 
plaques and fibrillary tangles. Despite the enormous efforts 
carried out by academic institutions and pharmaceutical 
industries, AD is an illness with unmet medical needs since the 
only drugs available in clinic (i.e., acetylcholinesterase (AChE) 
inhibitors and a NMDA receptor antagonist) have symptomatic 
and palliative effects and do not modify the course of the 
disease.[1,2] 
The most exploited hypothesis for the origin of AD is the one 
related to the amyloid cascade,[3] which singles out low 
molecular weight aggregates, fibrils and plaques of the amyloid 
beta peptide (Aβ, a peptide of 40 or 42 residues) as the cause of 
AD, since their presence interrupts the synaptic connections, 
precludes the right inter-neuron orientation and ultimately leads 
to neuronal death.[4,5] The Aβ peptides are produced by the 
hydrolysis of the amyloid precursor protein (APP) by two 
aspartic proteases, γ- and β-secretase (BACE-1), and the low 
molecular weight Aβ oligomers have been associated to 
neurotoxic effects.[6] The last decade has witnessed an all-out 
effort to discover inhibitors of these two enzymes that could 
become drug leads for the treatment of AD, but all the 
candidates have failed either at pre-clinical or clinical stages.[1,2] 
The inhibition of Aβ peptide aggregation has become an 
important target as well for drug lead discovery, although no Aβ 
aggregation inhibitor has surpassed the clinical trials either. On 
the other hand, Inestrosa et al.[7] have shown that the peripheral 
anionic site (PAS) in AChE could be an additional therapeutic 
target, since it is a nucleation site for the Aβ peptide aggregation 
and hence its inhibition could hinder this process. Finally, the 
inhibitors of AChE could also inhibit butyrylcholinesterase 
(BChE), and therefore have a bearing on the cholinergic 
pathway by precluding the hydrolysis of acetylcholine and 
probably enhancing (albeit temporarily) cognition in AD patients. 
Furthermore, preventing the neurotoxic effects of reactive 
oxygen species (ROS) with radical scavengers and/or inhibiting 
their formation with monoamine oxidase (MAO) inhibitors, which 
block the catalytic generation by MAO of hydrogen peroxide, a 
precursor of ROS, could be also an important strategy to tackle 
AD.[8,9] 
The great variety of targets opens the door to a new approach 
aimed at the discovery of molecules addressing simultaneously 
multiple targets of AD. This novel paradigm, which deviates 
radically from the traditional “one target-one molecule strategy”, 
has recently received increasing attention.[10-22] The major hurdle 
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in the search for multitarget leads lays on the substantial 
functional and structural differences amongst the targets, an 
issue that hinders drastically this therapeutic strategy. 
Coumarins are natural phytochemicals showing a wide range of 
pharmacological activities such as hepatoprotective, 
antiinflammatory, antitumor, antiallergic, antiviral, antifungal, 
antimicrobial, antiasthmatic, antioxidant, antinociceptive, 
antidiabetic and antidepressant effects,[23] as well as anti-
amnesic and memory restorative functions.[24] 
The potential engagement of the aromatic coumarin ring in 
hydrophobic, π-π and π-cation interactions, and in hydrogen 
bonding with its lactonic group, makes coumarins efficient 
ligands of many therapeutically relevant targets.[23-27] 
Many naturally occurring, as well as chemically synthesised 
coumarins, have been proposed as potential AD therapeutics, 
chiefly for their inhibitory activity against AChE and/or BChE. [23, 
28-33] Some coumarins act also on other AD related targets like 
Aβ aggregation[34] and BACE-1.[35,36] The selective, or multiple, 
activity of coumarins against AD protein targets has been shown 
to depend on substitution pattern and type of substituents. The 
recognition of key structural features of coumarin template and 
substituents for a selective or multiple pharmacological activity 
has helped in the design and synthesis of new analogues with 
high potency and selectivity against one target, e.g., AChE, or 
with a multiple activity resulting from a different combination of 
AChE, BACE-1 and Aβ aggregation,[14,35] or MAO inhibition.[37] 
For instance, positions 3, 4 and 7 of the coumarin were the most 
favorable for adding an amino fragment, through a flexible tether, 
to get a dual binding to both PAS and CAS in AChE and to 
afford inhibitors with high potency and selectivity over BChE.[23] 
Similar substitutions, mainly at 4 and 7 positions allowed the 
synthesis of potent and selective MAO-B inhibitors[38-43] and of 
MAOB-AChE dual inhibitors.[44,45] 
 
Recently, we have proposed an in silico procedure for the 
design of multitarget leads aimed at amyloid cascade and 
cholinergic pathways in AD.[19] Its first application led us to the 
discovery of a family of substituted indoles that inhibited Aβ 
aggregation, BACE-1, BChE and AChE by binding both its 
catalytic anionic site (CAS) and PAS.[19] The initial step of the 
protocol relies on a database search of compounds that comply 
with a pharmacophore proposed by us. One of the features of 
this template is a hydroxyethylamino group that is of the 
essence for the specific anchoring of the resulting compounds to 
the catalytic machinery of BACE-1. 
As a result of our database search of hydroxyalkylamino 
compounds with the structural requirements to interact with the 
catalytic dyad of BACE-1, we discovered a series of known 8-
aminomethyl-7-hydroxy coumarins (see Figure 1) in several 
chemical libraries. The systematic literature exploration led us to 
identify some Mannich bases of the 7-hydroxy-4-methyl 
coumarin (R”=Me) whose analogues exhibited antiviral activity 
against Flaviviradae.[46]  
In this work we propose a novel coumarin-based scaffold 
indicated in Figure 1 for the search of multitarget leads. The 
results of docking simulations for AChE and BACE-1 as well as 
molecular dynamics (MD) based simulations for Aβ aggregation 
predicted that our first generation coumarin derivatives should 
inhibit only the first of these targets, an outcome that was 
confirmed later by in vitro assays. 
 
Figure 1. General structure of the coumarins found in our searches, showing 
in red the molecular fragment required for the potential interaction with the Asp 
dyad in BACE-1. 
The negligible binding affinity for BChE of the initial set of AChE 
binders suggested that these compounds bind to the PAS in 
AChE, as observed for other coumarin derivatives.[23] In order to 
improve binding affinity, especially for BChE, we proposed a 
second generation of ligands that contain an anilino group 
separated from the coumarin fragment by a variable length 
tether. While the AChE inhibitory potency remained close to the 
one observed in the first series, a higher BChE inhibitory 
potency generally resulted for these new derivatives. A final 
structural modification involving the N-substitution of the 8-
aminomethyl moiety with a N-benzylpiperidine, that bears a 
protonatable nitrogen able to establish π-cation interactions in 
the CAS of AChE, led to the most potent AChE inhibitor of the 
whole series, endowed also with moderate BChE and Aβ 
aggregation inhibition.  
 
Results and Discussion 
The protocol for the in silico evaluation of the affinity to the 
chosen therapeutic targets included docking calculations for the 
enzymes AChE and BACE-1 and MD simulations for the binding 
to the Aβ peptide. A summary of the methods followed in the 
calculations is given in the Supporting Information and for full 
details see reference 19. 
AChE docking simulations. 
The relative small size of the first coumarins precludes their 
simultaneous binding to both the CAS and PAS of AChE. For 
this reason, we searched for binding hits through separate 
docking simulations focused either at the CAS or at the PAS. As 
seen from the results shown in Table 1, in all cases the top 
scoring function displays a hit both at the CAS and PAS binding 
regions. In many cases, the scoring value differences between 
the CAS and PAS sites were rather small, although in most 
instances the scoring value was higher for CAS than for PAS. 
This outcome raised the possibility that the ligands could bind to 
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Table 1. Coumarin docking results to the CAS and PAS in TcAChE using ChemPLP as scoring function. 
 
Compound R Scoring (PAS) Scoring (CAS) Compound R Scoring (PAS) Scoring (CAS) 
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76.82 76.10     
 
In Figure 2 the resulting binding poses of compound 5 at both 
the CAS and PAS of TcAChE are shown. As seen from this 
figure, the ligand was able to make π-stacking interactions with 
Phe 330 and Trp 84 at the CAS and the same type of 
interactions with Tyr 70 and Trp 279 at the PAS.  
BACE-1 docking simulations. 
The results for the docking calculations of the candidate leads to 
BACE-1 are shown in Table S1 (see Supporting Information). As 
mentioned in the Methods section of the Supporting Information, 
the docking into BACE-1 was performed with three protein 
templates that differ in the degree of flap opening. As seen from 
table S1, there was a very limited consensus on the capabilities 
of this set of coumarins as BACE-1 binders. The docking 
calculations displayed hits only with the ChemScore function 
and an open flap or with the GoldScore function and a half-open 
flap, and only three coumarins (2, 5 and 15) out of the 27 
analogues studied displayed hits for more than one scoring 
function or flap opening.  




Figure 2. Top-score binding pose of compound 5 bound either to the CAS 
(carbons in cyan, right) or to the PAS (carbons in green, left) of TcAChE, as 
predicted by our docking calculations. 
Aβ  peptide binding simulations. 
In previous aggregation inhibition studies using the same MD 
protocol[19] we could rank the capability of our compounds to 
inhibit aggregation by evaluating their aptitude to interrupt the 
formation of a hairpin turn, a structural motif that has been 
proposed as the possible template for Aβ aggregation. Figure S3 
(see Supporting Information) displays the Aβ peptide intra-
residue contact time in the presence and absence of our 
candidate ligands. As seen from this figure, only compound 5 
precluded to some extent the formation of a beta hairpin. 
 
Taken as a whole, our calculations predicted that the primary 
target of our initial set of coumarins was AChE. In order to 
validate our results, and eventually extend the biological activity 
to other AD targets we designed, synthesized and assayed a 
number of additional coumarins. Since previous studies[28-30] 
have pointed out that the coumarin scaffold binds to the PAS of 
AChE we performed also BChE inhibition as well as propidium 
competitive binding assays (see below). 
Synthesis and binding assays for AD targets of novel 
coumarins. 
Coumarin derivatives 5, 6, 10, 17, 25, 26 and 27 were prepared 
in moderate to good yields by Mannich condensation of 
commercially available 7-hydroxy-4-methylcoumarin, the 
appropriate amine, and formaldehyde in refluxing ethanol, as 
indicated in Scheme 1.  
 
Scheme 1. Synthetic route for the coumarin derivatives. 
The results from the experimental binding assays of BACE-1,[19] 
inhibition of electric eel AChE (eeAChE) and horse serum BChE 
(hsBChE),[47] as well as the ThT Aβ aggregation inhibition 
assay,[48, 49] are shown in Table 2. They indicate that the target to 
which these compounds bind the strongest is AChE, very much 
in support of the results of our calculations. The binding to the 
other targets was much weaker. For instance, our results 
indicated that only compounds 5 and 10 inhibited 
Aβ aggregation at a level similar to 9,10-anthraquinone (nearly 
30% at 100 µM).[50] The lack of substantive binding affinity for 
BChE should have a bearing on the AChE site to which these 
ligands bind. It is known that while AChE and BChE have highly 
homologous catalytic sites, the PAS of AChE and the 
corresponding binding region of BChE share a very low 
homology. For instance, the key aromatic residues Trp 279 and 
Tyr 70 in TcAChE are replaced in hsBChE by non-aromatic 
residues. Hence, it may be surmised that aromatic leads (like 
the coumarins studied in this work) that inhibit AChE but do not 
inhibit BChE would likely bind to the former enzyme at the PAS. 
Previous studies on the binding site of coumarins substituted at 
position 7 in AChE have also suggested that these compounds 
bind to the PAS. [28-30,51,52] 
Since it is known that coumarin derivatives bind both MAO 
isoforms[38-43] we also performed MAO-A and MAO-B inhibition 
tests on rat brain mitochondrial homogenates[39] for compounds 
10, 26 and 27 and found that the inhibition was below 10% at 20 
µM (data not shown).  
Table 2. Biochemical assay results for the first generation of coumarin 
derivatives. 
Compound ee AChE[a] hs BChE[b] Aβ (1-40)[c] BACE-1[d] 
5 6.5 ± 0.8 0 20 ± 4 27.91 
6 6.0 ± 0.6 11 ± 1 6 ± 2 23.00 
10 7.9 ± 0.7 0 33 ± 4 23.69 
17 7.7 ± 0.1 0 0 27.07 
25 5.8 ± 1.6 0 0 21.13 
26 7.3 ± 1.1 12 ± 3 5 ± 4 27.26 
27 5.1 ± 1.6 13 ± 4 4 ± 1 21.63 
 [a] IC50 (µM). [b] %Inh. @ 10µM. [c] %Inh. @ 100µM. [d] %Inh. @ 1mM. 
Design, synthesis and binding assays of second-generation 
coumarins 
It is known that compounds that fit both the PAS and CAS in 
AChE, named dual binding site inhibitors, might include two 
aromatic fragments, or one aromatic and one aminic fragments, 
separated by a tether that should span the gorge between both 
sites. Indeed, previous attempts to obtain dual binding site AChE 
inhibitors explored charged fragments, i.e. quaternary 
ammonium salts and protonated amines, eventually capped by 
an aromatic group, at various positions of coumarins other than 
8. Most of the structural variations rely on substitution at 
positions 3[30,35] and 7.[28,29,45] 
Since the 7-hydroxy-4-methylcoumarin moiety seemed to fit well 
into the PAS, we decided to generate a new set of compounds 
bearing an anilino motif separated by different tethers from the 
coumarin ring (see Scheme 2).  
The Mannich condensation was carried out as before, using 
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appropriate diamine and formaldehyde in refluxing ethanol. The 
required acyclic diamines were prepared as indicated in the 
Supporting Information starting from commercially available and 
inexpensive ω-amino alcohols. The use of N,N’-dimethylated 
diamines in the Mannich condensation afforded the expected 
coumarins 28-30 in good yields (Scheme 2). However, the use 
of primary amines (N-phenylalkane-1,n-diamines where n = 2, 3, 
5) afforded the cyclic derivatives 31-33 through a reaction with 
two equivalents of formaldehyde. Although it is known that 
primary amines react with two equivalents of formaldehyde to 
give the corresponding dihydrobenzoxazines,[53,54] we observed 
that diamines with a spatial linker of 2 or 3 carbon atoms gave 
instead the corresponding imidazolidine 31 or 
perhydropyrimidine 32, but when the two amines were 
separated by 5 carbon atoms the reaction favored the formation 
of the dihydro-1,3-oxazine 33. 
 
Scheme 2. Synthetic route for second and third generation coumarin 
derivatives. Reagents and conditions: a) MeHN(CH2)nNMePh (n = 3-5), H2CO, 
EtOH, reflux, 6h; b) H2N(CH2)nNHPh (n = 2, 3, 5), H2CO, EtOH, reflux, 6h; c) 
1-(1-Benzylpiperidin-4-yl)-N-methylmethanamine, H2CO, EtOH, reflux, 6h. 
The results of the experimental binding assays in AChE and 
BChE, as well as the ThT Aβ aggregation inhibition are shown in 
Table 3. As seen in this table, all compounds display affinity for 
AChE, but the only compounds that displayed dual AChE-BChE 
affinity were some of those containing the additional annular 
structure (32 and 33). The only compound with an additional ring 
that showed lower affinity for BChE was 31, a result that could 
be related to the ring size, which was the smallest (5-membered) 
amongst these compounds. Compounds 28-30, structurally 
close to 32 but more flexible, bound weakly to BChE, a result 
that indicated that their end anilino group (other than the 
coumarin moiety) did not bind efficiently to the CAS of AChE. It 
would seem that the additional ring in compounds 32 and 33 
placed the anilino moiety in the right orientation to bind more 
efficiently BChE. In addition, compound 33 was the only 
compound displaying some degree of inhibition of Aβ 





Table 3. Assay results for second and third generation candidates. 
Compound ee AChE[a] hs BChE[b] hs BChE[c] Aβ (1-40)[d] 
28 7.6±0.8 38±3 -- 0 
29 7.7±0.4 27±1 -- 0 
30 5.2±0.5 41±1 -- 0 
31 9.9±0.6  41±3 -- 6±2 
32 7.2±0.5 -- 5.3±0.3 0 
33 6.5±0.1  -- 4.7±0.4 20±2 
34 0.83±0.14  -- 15 ±3 28±4 
 [a] IC50 (µM). [b] %Inh. @ 10µM. [c] IC50 (µM). [d] %Inh. @ 100µM. 
 
Even though our step-wise molecular design led to two 
interesting ChE inhibitors exhibiting micromolar affinity towards 
both AChE and BChE, i.e. compounds 32 and 33, we designed 
a final molecule aiming at the recovery of a π-cation and π-π 
interactions in the CAS of AChE and possibly of BChE. A N-
benzylpiperidine moiety, present also in the well known AChE 
inhibitor drug donepezil (E2020),[55] was then attached at 
position 8 at an appropriate distance from the coumarin ring to 
yield compound 34 (Scheme 2). The inhibitor design (also used 
by other authors)[20,21] was validated by means of perspective 
docking calculations on TcAChE that returned the best 
consensus with the largest number of hits amongst the different 
scoring functions.  
It is worth noting that the structure of TcAChE bound to 
donepezil reveals a singular binding mode that differs from the 
ones displayed by many other potent AChE inhibitors. While a 
large number of AChE ligands have aromatic fragments that 
interact simultaneously with side chains of aromatic amino acids 
through a face-to-face π-π interactions, the aromatic ends of 
donepezil interact only with one aromatic side chain in an ‘open 
face’ sandwich pose.[56,57] We performed docking simulations to 
predict binding poses of compound 34, using as a template the 
3D structure (1EVE) of the TcAChE-donepezil complex.[56] 
Figure 3 displays one of the top-score binding poses of 34, 
ranked through ChemPLP evaluation function, along with the X-
ray determined binding pose of donepezil. This figure displays 
the ‘open-faced’ sandwich interaction between the coumarin 
moiety and Trp 279 in the PAS and between the N-benzyl group 
and Trp 84 in the CAS of TcAChE, similarly to the interaction 
observable for donepezil.[56] Notice that the N-benzyl group 
occupies the CAS region in accordance with our design aims.  
Very satisfactorily the AChE inhibition assay fully confirmed the 
docking prediction as compound 34 resulted the most potent 
inhibitor of the whole series of prepared coumarins with a sub-
micromolar IC50 (0.83 µM). 
 
To gain further insights into the mechanism of AChE inhibition 
by compound 34, its kinetic of inhibition and ability to displace 
propidium from PAS of AChE were assayed as reported in 
sections below. 
O OHO
7-hydroxy-4-methylcoumarin 28 (n = 3)29 (n = 4)



















33 (n = 5)31 (n = 2)32 (n = 3)




Figure 3. Binding pose of compound 34 (carbons in cyan) resulting from 
docking calculations superimposed to the X-ray crystal structure of donepezil 
(carbons in purple) in the TcAChE-inhibitor complex.[56] 
As expected, the results from the experimental binding assays 
on BACE-1, carried out on compounds 31, 32 and 34, showed a 
low inhibition (below 20% at 100 µM, data not shown). MAO-A 
and MAO-B inhibition assays for compounds 28, 30, 31, 33 and 
34 showed an inhibition below 20% at 20 µM. 
Kinetic study of the eeAChE inhibition by compound 34 
Kinetics of eeAChE inhibition were assessed by using four 
different concentrations of inhibitor 34 (0 to 8 µM) and six 
concentrations of substrate acetylthiocoline (0.033 to 0.2 mM). 
As expected, Lineweaver-Burk plot in Figure 4 suggested a 
mixed-type inhibition mechanism, typical of dual binding site 
inhibitors interacting at both the CAS and PAS.[30] Measured Ki 
for 34 was 1.43±0.25 µM.  
 
 
Figure 4. Lineweaver-Burk graphs for inhibition kinetics of compound 34. 
Concentrations of inhibitor are reported in insets. 
Propidium displacement assay on compound 34 and other 
selected coumarins. 
Propidium displacement assays were conducted at 100 µM 
concentration. Propidium, is a specific ligand of PAS of AChE[58] 
and its displacement indicates that the tested inhibitor binds to 
this site and that the higher the inhibition potency, the lower the 
concentration needed to displace propidium. It is worth 
reminding that the concentration of inhibitor necessary to 
displace propidium is around two orders of magnitude higher 
than its IC50 value. For instance, the concentration required to 
displace propidium by ligands with IC50 in the high nanomolar 
range is generally in the micromolar range.[59] The results from 
our propidium displacement assay are shown in Table 4. For a 
straightforward comparison among our inhibitors and donepezil, 
a well known dual binding site inhibitor of AChE, the percentage 
of propidium displacement was normalized to the maximum 
effect produced by donepezil (65±2% propidium displacement in 
AChE). As seen in Table 4, the relative percentage of 
displacement of our tested coumarins was up to 89% of the 
maximum effect of donepezil. Compound 34 exhibited 57% of 
relative propidium displacement and a high displacement was 
observed for first generation coumarins 5 (66%) or 6 (69%), and 
even higher for 17 (89%) or 26 (82%). High relative 
displacement values were measured also for second generation 
coumarins with a few exceptions, e.g. compound 28 (34%).  
Table 4. Percentage of propidium displacement by coumarin candidates 
normalized to the maximum effect of donepezil. 
Compound %Disp @100 µM Compound %Disp @100 µM 
5 66.24±1.06 28 33.78±2.39 
6 69.03±4.52 29 48.89±0.59 
10 63.93±3.32 30 52.95±4.84 
17 89.05±3.97 31 42.61±1.63  
25 58.85±1.99 32 54.03±1.27 
26 81.98±3.30 33 56.41±4.29 
27 54.22±0.21 34 56.99±1.20  
 
Conclusions 
A search based on a multitarget pharmacophore previously 
proposed[19] has enabled us to find a number of 8-aminomethyl-
7-hydroxy-4-methyl coumarins as suitable scaffolds that could 
fulfill our polypharmacology lead search against AD. These 
compounds contain some of the structural characteristics that 
could make them good binders for amyloid cascade targets as 
well as for cholinergic targets. For instance the hydroxyl and 
amino groups could anchor the molecule to the Asp dyad in 
BACE-1, while the coumarin ring could bind to the PAS of AChE. 
The resulting leads (with a large variety of aminomethyl 
substituents at position 8) have a substitution pattern that has 
been rarely explored for ChE inhibition,[60] and never as BACE-1 
or aggregation inhibitors. A protocol previously developed in our 
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laboratory was applied to determine which AD therapeutic 
targets could have been modulated by these compounds. The 
results of our simulations predicted that these compounds 
present a consensus only as ChE binders, an outcome validated 
by enzyme inhibition assays on ChE and BACE-1 and inhibition 
assay of Aβ aggregation assessed by the ThT fluorescence 
method.[49] This outcome provides further proof for the reliability 
of our computer aided protocol[19] for the search of multitarget 
leads. 
Given their size, our inhibitors could bind either the PAS or CAS 
sites in AChE, forming π-cation and π-π interactions with key 
aromatic residues. Many of the exit poses indicated that the 
scoring functions did not differentiate between the two binding 
sites. Previous studies with a different 7-hydroxycoumarin, that 
is the 3-chloro-7-hydroxy-4-methylcoumarin, demonstrated that 
this inhibitor bind to the PAS of AChE. Only when some key 
aromatic residues of the PAS were mutated to non-aromatic 
ones, the coumarin was able to bind to the CAS.[52] 
To generate dual binding site inhibitors we proceeded to enlarge 
the coumarin substituent at position 8, capping it with anilino and 
finally with a benzylamino moiety. The synthesis led to two 
groups of compounds that differentiate themselves in the 
presence or absence of an additional ring (see Scheme 2). 
Compound 34 was the candidate that displayed the highest 
binding affinity for AChE reaching a sub-micromolar IC50 (0.83 
µM), while keeping a µM affinity for BChE. This compound bears 
some of the traits of donepezil (Aricept or E2020),[61] one of the 
drugs used in clinic for the palliative treatment of AD. As 
donepezil, inhibitor 34 contains an N-benzylpiperidine fragment 
and shares a similar binding mode at the PAS and CAS of AChE 
as illustrated in Figure 3. Kinetic studies suggested a mixed type 
mechanism of inhibition indicating that compound 34 could be a 
dual binding site inhibitor as donepezil.  
Our inhibition data would indicate that the presence of the 
additional ring is essential for the binding at BChE with affinities 
similar to that of AChE (see Table 3). As mentioned before, the 
only exception was compound 31, a weak BChE binder, since it 
contains an imidazolidine group instead of the larger 
hexahydropyrimidine (present in 32). Finally, compound 34 
could be considered as a promising lead for further structural 
modifications aimed at improving its inhibition potency at AChE 
and expanding its activity towards other therapeutic targets of 
amyloid cascade, such as BACE-1 and Aβ-aggregation. 
 
 
Supporting Information. Computational methodology details as 
well as experimental procedures for the syntheses and in vitro 
biological evaluation of compounds listed in Tables 2 and 3. 
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Application of a computer protocol to the search of multitarget leads for Alzheimer’s disease led us to coumarine 
derivatives with a scantily studied susbtitution pattern that are dual site binders of AChE and also inhibit BChE and amyloid 
aggregation. 
 
